There are currently 6 active clinical trials seeking participants for Renal Impairment research studies. The states with the highest number of trials for Renal Impairment participants are Florida, California, Minnesota and Texas.
A Clinical Study of MK-1084 in Participants With Renal Impairment (MK-1084-010)
NCT06814119
Recruiting
The goal of this study is to learn what happens to MK-1084 levels in a person's body over time. Researchers will measure what happens to MK-1084 levels in the body when it is given to people with moderate or severe renal impairment (RI) (meaning the kidneys do not work properly) as compared to people who are in good health. Researchers also want to learn about the safety of MK-1084 when it is given to people with RI and if people with RI can tolerate it.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/05/2025
Locations: Orlando Clinical Research Center ( Site 0002), Orlando, Florida +1 locations
Conditions: Healthy, Renal Impairment
Register for Updates
Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234
NCT06845813
Recruiting
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of single subcutaneous dose of AZD6234 with end stage renal disease, severe, and possibly moderate and mild renal impairment in comparison to a matched healthy control group.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/30/2025
Locations: Research Site, Lake Forest, California +3 locations
Conditions: Renal Impairment
Register for Updates
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
NCT06911320
Recruiting
To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/27/2025
Locations: Atea Study Site, Orlando, Florida +1 locations
Conditions: Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Register for Updates
An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function
NCT06962774
Recruiting
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe renal impairment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/30/2025
Locations: Panax Clinical Research, Miami Lakes, Florida +3 locations
Conditions: Renal Impairment
Register for Updates
A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis
NCT06723535
Recruiting
The purpose of this study is to assess the effect of severe renal impairment (RI) and end-stage renal disease (ESRD) with intermittent hemodialysis (IHD) on the pharmacokinetics and safety of BMS-986278. This study plans to use a staged design based on RI severity.
Gender:
ALL
Ages:
Between 18 years and 84 years
Trial Updated:
03/11/2025
Locations: Clinical Pharmacology Of Miami, LLC, Miami, Florida +3 locations
Conditions: Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
Register for Updates
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
NCT06496217
Recruiting
Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/17/2024
Locations: MBX Biosciences Investigational Site, Miami, Florida +2 locations
Conditions: Renal Impairment
Register for Updates